A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

Liver International

Volumn 34, Issue 10, 2014, Pages 1550-1559

  Ferenci, Peter ^a   Aires, Rodrigo ^b   Ancuta, Ioan ^c   Arohnson, Andrew ^d   Cheinquer, Hugo ^e   Delic, Dragan ^f   Gschwantler, Michael ^g   Larrey, Dominique ^h   Tallarico, Ludovico ⁱ   Schmitz, Manuela ^j   Tatsch, Fernando ^k,m   Ouzan, Denis ^l  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b The Goiás Federal University Clinical Hospital   (Brazil)

^c CANTACUZINO INSTITUTE   (Romania)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^f CLINICAL CENTER OF SERBIA   (Serbia)

^g WILHELMINEN HOSPITAL   (Austria)

^h HÔPITAL SAINT ELOI   (France)

ⁱ Ospedale Elena d'Aosta   (Italy)

^j IST GmbH   (Germany)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l INSTITUT ARNAULT TZANCK   (France)

^m ABBVIE INC   (United States)

more..

Author keywords

Caucasian; Hepatitis C; Peginterferon alfa ribavirin; Predictive scoring; PROPHESYS; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; VIRUS RNA; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CAUCASIAN; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT SELECTION; PREDICTIVE VALUE; PROBABILITY; SCORING SYSTEM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; AGE; BLOOD; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COMBINATION; GENETICS; HEPACIVIRUS; METHODOLOGY; MIDDLE AGED; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; COHORT STUDIES; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RESEARCH DESIGN; RIBAVIRIN; RNA, VIRAL;

EID: 84908127708     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12439     Document Type: Article

References (27)

1. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
4. FDA Drug Safety Communication: Serious skin reaction after combination treatment with the hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin (issued December 19, 2012). Available at http://www.fda.gov/Drugs/DrugSafety/ucm332731.htm (accessed 21 January 2013).
5. Sarrazin C, Berg T, Cornberg M, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: 57-72.
6. Leroy V, Serfaty L, Bourlière M, et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French association for the study of the liver. Liver Int 2012; 32: 1477-92.
7. Omata M, Kanda T, Yu M-L, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-35.
8. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
9. Bronowicki J, Hezode C, Bengtsson L, et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial [abstract 1094]. J Hepatol 2012; 56 (Suppl. 2): S430-1.
10. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56: 2039-50.
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
12. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
13. Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50: 1045-55.
14. Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010; 139: 1972-83.
15. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
16. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-12.
17. Scherzer TM, Stättermayer AF, Strasser M, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40kD)/ribavirin. Hepatology 2011; 54: 1518-26.
18. Ferenci P, Aires R, Beavers KL, et al. Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. Hepatol Int 2014; 8: 83-93.
19. Ferenci P. Optimal treatment duration for patients with HCV genotype 1 infection. J Viral Hepat 2011; 18(Suppl. 2): 7-13.
20. Ferenci P, Reddy KR. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antivir Ther 2011; 16: 1187-201.
21. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 2014; 59: 71-7.
22. Hézode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) [abstract 8]. J Hepatol 2012; 56(Suppl. 2): S4.
23. Aronsohn A, Jensen D. Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology 2012; 56: 1591-2.
24. Hunyady B, Makara M, Gervain J, et al. Treating naive chronic hepatitis C patients with dual (peginterferon/ribavirin, SOC) or triple (SOC + protease inhibitor, PI) therapy in Hungary. An approach with limited resources [abstract 1118]. J Hepatol 2012; 56(Suppl. 2): S440-1.
25. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
26. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
27. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-50.